Drugs for Myalgic Encephalomyelitis/chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 30)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
2 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
3 |
|
poly(I).poly(c12,U) |
|
Phase 3 |
|
|
|
4 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
5 |
|
Glycerol |
Approved, Investigational |
Phase 2 |
|
56-81-5 |
753 |
Synonyms:
1,2,3-propanetriol
1,2,3-Propanetriol
1,2,3-trihydroxypropane
1,2,3-Trihydroxypropane
Bulbold
Cristal
e 422
Emery 916
Glyceol opthalgan
Glycerin
Glycerin, anhydrous
Glycerin,anhydrous
Glycerine
glycérine
Glycerinum
Glyceritol
Glycerol
glycérol
|
Glycerolum
Glycyl alcohol
Glyrol
Glysanin
Glyzerin
Gro
IFP
Incorporation factor
Mackstat H 66
Monoctanoin component D
Oelsuess
Ölsüß
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Trihydroxypropane
Tryhydroxypropane
|
|
6 |
|
rituximab |
Approved |
Phase 2 |
|
174722-31-7 |
10201696 |
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
Ig gamma-1 chain C region
Mabthera
|
MabThera
Rituxan
rituximab
rituximab-abbs
rituximab-pvvr
|
|
7 |
|
Etanercept |
Approved, Investigational |
Phase 2 |
|
185243-69-0 |
|
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
etanercept
Etanercept
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
Etanercept (USAN/INN)
etanercept-szzs
|
etanercept-ykro
p75
p80 TNF-alpha receptor
Recombinant human TNF
rhu TNFR:Fc
rhu-TNFR:Fc
TNF-R2
TNFR-Immunoadhesin
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
|
|
8 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
9 |
|
Adrenocorticotropic Hormone |
|
Phase 1, Phase 2 |
|
|
|
10 |
|
Corticotropin-Releasing Hormone |
|
Phase 1, Phase 2 |
|
|
|
11 |
|
Cola |
|
Phase 2 |
|
|
|
12 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
13 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
14 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
15 |
|
Antibodies |
|
Phase 2 |
|
|
|
16 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
17 |
|
Analgesics |
|
Phase 2 |
|
|
|
18 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
19 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
20 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
21 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
22 |
|
Pharmaceutical Solutions |
|
Phase 1 |
|
|
|
23 |
|
Zinc |
Approved, Investigational |
|
|
7440-66-6 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
24 |
|
Naltrexone |
Approved, Investigational, Vet_approved |
|
|
16590-41-3 |
5360515 |
Synonyms:
16590-41-3
16676-29-2
17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one
Antaxone
BIDD:GT0405
BPBio1_000146
BRD-K88172511-310-03-8
Bristol myers squibb brand OF naltrexone hydrochloride
Bristol-myers squibb brand OF naltrexone hydrochloride
BRN 3596648
BSPBio_000132
C07253
CCRIS 3506
Celupan
CHEBI:121459
CHEBI:7465
CHEMBL142
CID5360515
D05113
DB00704
Depade
Du pont brand OF naltrexone hydrochloride
EINECS 240-649-9
EN-1639A
HMS2089O11
HS-0002
HSDB 6750
Hydrochloride, naltrexone
Lacer brand OF naltrexone hydrochloride
lamepro Brand OF naltrexone hydrochloride
LS-92094
MLS002153483
MolPort-004-920-221
MorViva
|
Nalorex
Naltrexon
Naltrexona
Naltrexona [INN-Spanish]
naltrexone
Naltrexone
naltrexone (ReVia)
Naltrexone (USAN/INN)
Naltrexone [Usan:Ban:Inn]
Naltrexone [USAN:BAN:INN]
Naltrexone [USAN:INN:BAN]
Naltrexone Hcl
Naltrexone hydrochloride
Naltrexonum
Naltrexonum [INN-Latin]
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Nemexin
Orphan brand OF naltrexone hydrochloride
PDSP2_000847
Pharmazam brand OF naltrexone hydrochloride
Prestwick0_000116
Prestwick1_000116
Prestwick2_000116
Prestwick3_000116
PTI-555
ReVia
Schering plough brand OF naltrexone hydrochloride
Schering-plough brand OF naltrexone hydrochloride
SMP1_000206
SPBio_002071
Trexan
UM-792
UNII-5S6W795CQM
United drug brand OF naltrexone hydrochloride
Vivitrex
Vivitrol
Vivitrol (TN)
|
|
25 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
Synonyms:
(C6-C9)Alkyl alcohol
[CH2Me(OH)]
[OEtH]
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
1-Hydroxyethane
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
absolute alcohol
Absolute alcohol
Absolute Alcohol
Absolute ethanol
Absolute Ethanol
Absolute ethyl alcohol
AC1L19TW
AC1Q31MM
Aethanol
Aethanol [German]
Aethylalkohol
AHD 2000
AI3-01706
Alcare hand degermer
Alcare Hand Degermer
alcohol
Alcohol
Alcohol (ethyl)
Alcohol (USP)
Alcohol [USP]
ALCOHOL 5% IN D5-W
Alcohol anhydrous
Alcohol Anhydrous
Alcohol dehydrated
Alcohol denatured
alcohol etilico
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Absolute
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, Dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, Diluted
Alcohol, ethyl
Alcohol, grain
Alcohol, Grain
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool ethylique
Alcool Ethylique
Alcool éthylique
Alcool etilico
Alcool Etilico
Algrain
Alkohol
Alkohol [German]
Alkoholu etylowego
Alkoholu Etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
bmse000297
C00469
C2H5OH
C2H6O
Caswell No. 426
Caswell No. 430
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
|
CHEMBL545
CID702
Colamine
Cologne spirit
Cologne Spirit
Cologne spirits
D000431
D00068
DB00898
Dehydrated alcohol
Dehydrated ethanol
Dehydrated Ethanol
Denatured alcohol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Denatured Ethanol
Desinfektol el
Desinfektol EL
Diluted alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
Envision Conditioner Pdd 9020
EOH
EOX
Esumiru WK 88
ETA
etanol
Etanol
Etanolo
Etanolo [Italian]
ethanol
éthanol
Ethanol (9CI)
Ethanol [JAN]
Ethanol 200 proof
Ethanol 200 Proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol Vapor
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl alc
ethyl alcohol
Ethyl alcohol
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl Alcohol Anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl Hydrate
Ethyl hydroxide
Ethyl Hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
EtOH
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
grain alcohol
Grain alcohol
Hinetoless
HSDB 531
HSDB 82
Hydroxyethane
HYDROXYETHYL GROUP
I14-12648
IMS 99
Infinity pure
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated spirit
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
MolPort-001-785-844
NCGC00091458-01
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
potato Alcohol
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spirits OF wine
spiritus vini
Spiritus vini
Spirt
SY Fresh M
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
UNII-3K9958V90M
USAF EK-1597
WLN: Q2
|
|
26 |
|
Melatonin |
Approved, Nutraceutical, Vet_approved |
|
|
73-31-4 |
896 |
Synonyms:
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} acetamide
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-methoxy-N-acetyltryptamine
5-Methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
AKOS000276269
BAS 01281092
BIDD:ER0618
Bio-0635
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
ChemDiv2_003916
CID896
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
Lopac0_000787
Lopac-M-5250
LS-1623
M 5250
M1105
M-1200
M-1250
M5250_SIGMA
Melapure
Mela-T
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
|
Mélatonine
Melovine
ML1
MLS000859594
MLS001055382
MLS001240204
MolPort-000-737-883
MT6
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-acetamide
N-acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxytryptamine
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine melatonine
Nature'S Harmony
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
Night Rest
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Oprea1_104553
Oprea1_814234
Pineal Hormone
Posidorm
Prestwick_312
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
Sleep Right
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
Spectrum_000185
SPECTRUM1500690
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
STK386880
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
|
|
27 |
|
Antioxidants |
|
|
|
|
|
28 |
|
Protective Agents |
|
|
|
|
|
29 |
|
Narcotics |
|
|
|
|
|
30 |
|
Narcotic Antagonists |
|
|
|
|
|
Interventional clinical trials:
(show all 30)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) |
Completed |
NCT00215800 |
Phase 3 |
Ampligen |
2 |
Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months |
Unknown status |
NCT02444091 |
Phase 2 |
Cyclophosphamide |
3 |
Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome |
Completed |
NCT03613129 |
Phase 1, Phase 2 |
CT38 |
4 |
Fecal Microbiota Transplantation in Chronic Fatigue Syndrome - an RCT |
Recruiting |
NCT03691987 |
Phase 2 |
|
5 |
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab. |
Terminated |
NCT01730495 |
Phase 2 |
Etanercept |
6 |
Reducing Orthostatic Intolerance With Oral Rehydration in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
Active, not recruiting |
NCT02854683 |
Phase 1 |
Normal Saline |
7 |
New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
Unknown status |
NCT03502044 |
|
|
8 |
Sex Differences in Exercise-related Post-exertional Malaise in ME/CFS |
Unknown status |
NCT03331419 |
|
|
9 |
ME/CFS: Activity Patterns and Autonomic Dysfunction |
Unknown status |
NCT02948556 |
|
|
10 |
Use of a Monitor in ME/CFS |
Unknown status |
NCT01908036 |
|
|
11 |
Hypermobility and Obstructions in the Craniocervical Region Among Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
Completed |
NCT04399330 |
|
|
12 |
An Unicentric, Double-blind, Placebo Controlled, Phase IV Clinical Trial of Oral Melatonin Plus Zinc to Evaluate Relieving Self-reported Fatigue in CFS/ME |
Completed |
NCT03000777 |
|
|
13 |
Acceptance & Commitment Therapy for ME/CFS (Chronic Fatigue Syndrome) - an Open Case Trial |
Completed |
NCT03562325 |
|
|
14 |
A RCT Study on the Effect of Short and Long Cognitive Behaviour Therapy (CBT) in CFS/ME Patients |
Completed |
NCT00920777 |
|
|
15 |
Psychological Wellbeing in Adults With Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis |
Completed |
NCT02094820 |
|
|
16 |
Developing an Activity Pacing Framework for the Management of Chronic Pain/Fatigue. Stage III: Feasibility and Acceptability Studies |
Completed |
NCT03497585 |
|
|
17 |
An Initial Trial of ASARM: an Advanced Sleep and Rest Monitoring System for Treating Paediatric CFS/ME: Assessing Acceptability and Adaptation Into Current CBT Treatment Protocols |
Completed |
NCT02082730 |
|
|
18 |
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
Recruiting |
NCT04100915 |
|
|
19 |
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
Recruiting |
NCT02669212 |
|
|
20 |
Assessment of Exercise Response in Chronic Fatigue Syndrome / Myalgic Encephalomyelitis. |
Recruiting |
NCT03675087 |
|
|
21 |
Probing Metabolism, Circulating Inflammatory Molecules, Extracellular Vesicles and Immune Dysregulation in Individual Immune Cells in ME/CFS |
Recruiting |
NCT04026425 |
|
|
22 |
Cardiopulmonary Exercise Testing as a Diagnostic Tool and a Quantitative Measure of Post-exertional Malaise in Myalgic Encephalopathy/Chronic Fatigue Syndrome |
Active, not recruiting |
NCT02970240 |
|
|
23 |
Defining Autoimmune Aspects of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
Enrolling by invitation |
NCT03254823 |
|
|
24 |
Central Mechanisms of Chronic Pain and Fatigue Subtitle: Functional Imaging of Brain and Spinal Cord |
Enrolling by invitation |
NCT03075254 |
|
|
25 |
Complex Chronic Diseases Program Data Registry |
Enrolling by invitation |
NCT03409653 |
|
|
26 |
The ME-SH (Myalgic Encephalomyelitis in Stockholm-Harvard) Study: Structural Problems in Brainstem and Cervical Spine Cord in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome(ME/CFS) - a Case-control Study |
Not yet recruiting |
NCT04403854 |
|
|
27 |
The Influence of Epigenetic Modifications and Post-Exertional Malaise in People With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
Not yet recruiting |
NCT04378634 |
|
|
28 |
A Pilot Study for Continuous Monitoring of Physical Activity Using Activity Armbands for 6 Months: Assessment of Feasibility and Comparison to Self-reported Questionnaires |
Not yet recruiting |
NCT04195815 |
|
|
29 |
The Immune Effects of Low-dose Naltrexone in People With Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) |
Suspended |
NCT02965768 |
|
Naltrexone HCl |
30 |
Pilot Study of Alternative Treatments of Unexplained Chronic Fatigue |
Terminated |
NCT00983502 |
|
|
|